Results 231 to 240 of about 65,782,767 (266)

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Sub1 contributes to heart failure with preserved ejection fraction driven by aging in mice. [PDF]

Nat Commun
Zhao D, Lin L, Zhou Y, Wu J, Xu R, Li L, Zhang X, Lin H, Wang J, Dai K, Ding Z, Gao P, Wu J, Zou Y.   +13 more
europepmc   +1 more source

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era. [PDF]

Endocrinol Diabetes Metab
Mohamed ZI, Shidane AA, Abdiasis AM, Hussein MH, Ibrahim AO, Abdi AA, Hashi KI, Mohamud MA, Mohamed AJ.   +8 more
europepmc   +1 more source

The Relationship Between the Systemic Immune Inflammatory Index and Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction. [PDF]

Eurasian J Med
Şentürk B, Kış M, Çöllüoğlu T, Dursun H, Oktay Ç, Ekizler FA, Yılmaz MB.   +6 more
europepmc   +1 more source

Short-Chain Fatty Acids in Heart Failure with Preserved Ejection Fraction: Pathophysiological Roles and Therapeutic Potential. [PDF]

Int J Mol Sci
Lyu Y, Hou J, Ma I, Mostoufi T, Jiang Y, Yang X, Gao WD.   +6 more
europepmc   +1 more source

Flexible wearable electronics for cardiovascular monitoring from surface signals to deep physiological insights

FlexMat, EarlyView.
This review organizes flexible wearable electronics for cardiovascular monitoring into four interconnected information layers: surface electrophysiology, hemodynamic sensing, vascular imaging, and biofluid biomarker analysis. This framework clarifies how electrical rhythm, vascular loading, structural and flow‐related features, and biochemical states ...
Qiao Chen, Hongwen Chen, Yuanyuan Li, Pingan Yang, Rui Li, Zhihao Zhou   +5 more
wiley   +1 more source

Heart-Lung Interactions in Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction. [PDF]

Compr Physiol
Prabala P, Raza F, Chesler NC.
europepmc   +1 more source

Targeting PKGIα Cys⁴² attenuates cardiac dysfunction in heart failure with preserved ejection fraction. [PDF]

Sci Adv
Su J, Zhao Y, Coleman P, Yang X, Holt M, Raabe J, Cuello F, Shah A, Shattock MJ, Zhang M, Burgoyne JR.   +10 more
europepmc   +1 more source

The diagnosis and subclassification of heart failure with preserved ejection fraction: a review. [PDF]

Heart Fail Rev
Creegan D, Starling RC, Hameed A, Daly MJ, O'Neill J.   +4 more
europepmc   +1 more source

Pitfalls of Therapies Targeting the Nitric Oxide Signaling Pathway in Heart Failure With Preserved Ejection Fraction. [PDF]

J Cardiovasc Pharmacol
Loeb SA, Tharp DL, Zawieja SD, Pal S, Abbate A, Isakson BE.   +5 more
europepmc   +1 more source